gbola amusa md cfa head hc research
sale trade et
sale trade et
share mil
creat bluematrix
cbio buy buy weak dalca nab
tuesday day new york citi catalyst
bioscienc provid updat hemophilia program say
phase i/ii dalcinonacog alfa dalca factor ix
deriv hemophilia inher immunogen
compani indic resum clinic trial dalca
on-going phase ii/iii trial marzeptacog alfa activ
marzaa factor viia fviia variant hemophilia inhibitor
shown reduct annual bleed rate abr median
compar pre-treat abr subject
complet studi bleed final treatment dose level
compani trade cash versu approxim
month nab controversi emerg see buy
opportun note dalca due enter phase iib studi
marzaa perhap catalyst modest cash burn
continu show util hemophilia patient inhibitor
dalca similar immunogen profil benefix
advanc phase iib studi dalca program recal
compani june report neutral antibodi nab
patient cohort phase i/ii studi dalca see june
research follow manag indic would thoroughli
investig potenti caus nab day
present catalyst indic perform comprehens studi
involv assess see slide human leukocyt antigen hla
genotyp risk factor immunogen dalca qualiti
drug product formul risk inject site reaction
isr induc nab compani util variou approach
assess profil dalca conclud see slide dalca
immunogen profil commerci use benefix
product qualiti dalca use phase i/ii studi compar
benefix rixubi consist isr observ
toxicolog studi subject center nab
issu previous report see page differ
hla type glutamin mutat see slide
compani indic rare cite seen
individu case enter european associ
haemophilia alli disord eahad databas follow-
manag ask whether silico analysi util hla
haplotyp associ nab perform catalyst indic
analysi pend visibl whether data
directli address role haplotyp potenti rare
yet undetermin haplotyp immunogen catalyst note given
find dalca inher immunogen nab may
pleas refer import disclosur inform regul analyst certif found page report
arisen due rare genotyp and/or certain hla type indic nab rare event observ
within restrict popul go forward compani intend advanc dalca phase iib trial
exclud rare genotyp seen phase i/ii cohort subject candid risk develop
nab catalyst also go broaden subject pool expand divers phase iib candid note
find point previou postul nab issu like specif dalca platform issu
see septemb research
cb provid preclin data dri age-rel macular degener
dalca initi phase iib studi hemophilia
marzaa present eahad phase ii data hemophilia a/b inhibitor
dalca present eahad phase i/ii data hemophilia
marzaa end phase ii meet regul hemophilia a/b inhibitor
marzaa file ind acquir hemophilia
marzaa provid updat phase ii data isth hemophilia inhibitor
dalca present phase iib data nab analysi isth hemophilia
marzaa provid end phase ii data hemophilia inhibitor
decemb cbio buy day dose nab isr marzaa
septemb cbio buy investor dinnerth market ascrib pii/iii marzaa
june cbio buy cb marzaa manufactur differ posit
june discount cash marzaa data upcom
march cbio buy posit ahead marzaa
februari cbio buy pt phase i/ii cb data hemophilia
june reiter buy cb phase i/ii support valuat potenti hemophilia
catalyst bioscienc cbio price target base valu cbio discount minimum
market cap credibl comp hemophilia space plan move back typic valuat methodolog
 dcf driven patient-bas market model disclosur catalyst asset
risk achiev target price
clinic risk clinic studi marzaa hemophilia inhibitor might fail show efficaci subcutan
subq prophylact therapi might gener safeti issu exampl thromboembol event might lead
format anti-drug antibodi creat efficaci and/or safeti risk moreov trial cb
hemophilia might fail show efficaci subq therapi due nab might gener safeti issu
regulatori risk certainti catalyst drug approv reimburs us elsewher
regulatori pathway prove complex and/or time consum anticip could materially-
neg impact project target price even assum result catalyst franchis achiev
target endpoint product obtain regulatori approv risk-adjust project price target
would expos downward revis
commerci risk potenti catalyst indic may larg project highlight
competit hemophilia inhibitor roch unrat alnylam buy novo nordisk unrat shire
unrat highlight competit hemophilia unrat sanofi unrat novo nordisk shire
page
behr unrat alnylam neutral uniqur buy sangamo unrat freelin
therapeut privat addit catalyst build sale market medic affair infrastructur
us possibl global region
financ risk catalyst potenti need rais addit capit fund clinic trial perhap via equiti
financ reach profit potenti result share dilut sharehold
stock price volatil share price volatil common development compani biotechnolog sector
catalyst bioscienc found went public august merger targacept catalyst
focus therapi treatment hemophilia develop engin recombin clot
factor design subcutan administr compani lead asset engin activ factor vii marzaa
treatment hemophilia inhibitor phase ii/iii trial second asset engin factor ix cb
treatment hemophilia phase i/ii trial catalyst also engin activ factor
treatment coagul disord program treatment renal delay graft function cardiovascular
diseas dri catalyst headquart south san francisco california
page
rate price target histori catalyst bioscienc inc cbio
creat bluematrix
rate price target histori inc
rate price target histori inc
creat bluematrix
creat bluematrix
page
rate price target histori uniqur qure
creat bluematrix
distribut ratings/ib servic
analyst certif analyst respons cover secur report certifi view
express research report accur reflect person view compani secur analyst
respons cover secur report certifi part compens directli
indirectli relat specif recommend view contain research report
